1Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet, 1993, 342: 651-652.
2Wada N, Mukai M, Kohno M, et al. Prevalence of serum antimyeloperoxidase antineutrophil cytoplasmic antibodies ( MPOANCA) in patients with Graves′ disease treated with propylthiouracil and thiamazole. Endocr J,2002 ,49:329-334.
3Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves′ disease. Thyroid,2000,10:595-599.
4Sato H, Hattori M, Fujieda M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves′ disease treated with propylthiouracil. J Clin Endocrinol Metab, 2000,85:4270-4273.
5Gunton JE, Stiel J, Clifton-Bligh P, et al. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol, 2000 ,142:587-590.
6Ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother, 2002 ,36:130-147.
